On Aug. 23, 2020, the Mayo Clinic announced that with the FDA Emergency Use Authorization of convalescent plasma, the national Expanded Access Program (EAP) for convalescent plasma led by Mayo Clinic announced its intention to discontinue enrollment.

The EAP was designed to increase access to investigational convalescent plasma and evaluate the safety of this experimental therapy. The five-month program served 2,780 hospital and acute care facilities, with nearly 14,000 physicians enrolling 101,000 patients and reports of 71,000 infused to date.

The Expanded Access Program at Mayo Clinic grew from a national initiative of physicians and investigators from 10 institutions who self-organized to research the use of convalescent plasma during the COVID-19 pandemic.